Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CTSG | P08311 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21715380 | 0.89 | LMNA (0.48) | CYP4F2CYP4A11LMNAMAPTSMN1; SMN2 | |
| SCHEMBL30753435 | 0.89 | LMNA (0.48) | CYP4F2CYP4A11LMNAMAPTSMN1; SMN2 | |
| SCHEMBL3948116 | 0.87 | CYP4F2 (0.59) | CYP4F2CYP4A11LMNAMAPTSMN1; SMN2 | |
| SCHEMBL14874345 | 0.87 | CYP4F2 (0.59) | CYP4F2CYP4A11LMNAMAPTSMN1; SMN2 | |
| SCHEMBL490608 | 0.87 | CYP4F2 (0.51) | CYP4F2CYP4A11SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL5379790 | 0.87 | CYP4F2 (0.59) | CYP4F2CYP4A11MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL7687145 | 0.86 | CYP4F2 (0.67) | CYP4F2CYP4A11SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL5120475 | 0.85 | CYP4F2 (0.57) | CYP4F2CYP4A11LMNAMAPTALDH1A1 | |
| SCHEMBL6366424 | 0.85 | LMNA (0.54) | LMNAMAPTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL16318871 | 0.84 | CYP4F2 (0.56) | CYP4F2CYP4A11SMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268293-B2 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| CN-101163659-B | Antioxidants | MERCK PATENT GMBH | 2012-09-05 | — | — | CN | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| CN-101203278-A | Ultraviolet protection | MERCK PATENT GMBH (DE) | 2008-06-18 | — | — | CN | disclosed |
| CN-101163659-A | Antioxidants | MERCK PATENT GMBH (DE) | 2008-04-16 | — | — | CN | disclosed |
| EP-1871735-A1 | ANTIOXIDANTS | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871339-A1 | UV PROTECTION | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006111233-A1 | ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006111234-A1 | UV PROTECTION | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| US-6262064-B1 | AN ACTAHYDROBENZO(F)QUINOLINE-BASED COMPOUND | THE BOARD OF GOVERNORS FOR HIGHER EDUCATION | 2001-07-17 | — | — | US | disclosed |
| US-5863928-A | TREATMENT OF PSYCHOTIC DISORDERS, PARKINSON'S DISEASE; SEDATIVES | THE BOARD OF GOVERNORS FOR HIGHER EDUCATION THE STATE OF RHODE ISLAND AND PROVIDENCE PLANTATION. (US) | 1999-01-26 | — | — | US | disclosed |
| EP-0729458-A1 | OCTAHYDROBENZO[f]QUINOLINE-BASED RECEPTOR AGONISTS AND ANTAGONISTS | THE BOARD OF GOVERNORS FOR HIGHER EDUCATION STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995014006-A1 | OCTAHYDROBENZO[f]QUINOLINE-BASED RECEPTOR AGONISTS AND ANTAGONISTS | THE BOARD OF GOVERNORS FOR HIGHER EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS (US) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | CYP4F2 287/4885CYP4A11 486/4885LMNA 1949/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | CYP4F2 1045/4885CYP4A11 256/4885LMNA 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.